Tyra Biosciences, Inc.

NasdaqGS:TYRA Stock Report

Market Cap: US$740.1m

Tyra Biosciences Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:TYRA Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
25 Nov 24SellUS$88,773Canaan Management, Inc.Company5,272US$16.84
08 Nov 24BuyUS$19,836,066RA Capital Management, L.P.Company1,220,681US$16.25
08 Nov 24SellUS$31,696,800Boxer Capital Management, LLCCompany1,905,000US$20.55
07 Nov 24SellUS$1,284,133Canaan Management, Inc.Company74,582US$17.32
06 Nov 24SellUS$19,836,066Boxer Capital Management, LLCCompany1,220,681US$16.25
05 Nov 24SellUS$194,248Canaan Management, Inc.Company11,569US$17.01
01 Nov 24SellUS$2,282,656Canaan Management, Inc.Company138,711US$17.16
31 Oct 24SellUS$780,880MVA Associates, LLCCompany42,000US$20.63
30 Oct 24BuyUS$151,954Alan FuhrmanIndividual9,500US$16.00

Insider Trading Volume

Insider Buying: TYRA insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of TYRA?
Owner TypeNumber of SharesOwnership Percentage
Private Companies43,9390.0835%
Individual Insiders2,205,5974.19%
Hedge Funds4,661,1948.86%
General Public4,928,2279.37%
Institutions17,810,96733.9%
VC/PE Firms22,953,30443.6%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 22.2%.

Top Shareholders

Top 25 shareholders own 85.25% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
20.2%
RA Capital Management, L.P.
10,637,290US$149.7m2.12%1.91%
8.86%
BVF Partners L.P.
4,661,194US$65.6m0%2.13%
7.95%
Canaan Management, Inc.
4,179,857US$58.8m-5.22%43.82%
7.76%
Alta Partners LP
4,080,296US$57.4m0%89.71%
7.71%
Nextech Invest Ltd.
4,055,861US$57.1m0%9.85%
6.41%
FMR LLC
3,372,828US$47.5m0.78%no data
3.78%
TCG Crossover Management, LLC
1,989,103US$28.0m0%2.59%
2.88%
BlackRock, Inc.
1,516,172US$21.3m6.86%no data
2.58%
Todd Harris
1,355,927US$19.1m-8.22%no data
2.37%
The Vanguard Group, Inc.
1,245,408US$17.5m0.56%no data
2.03%
Janus Henderson Group plc
1,067,196US$15.0m0%0.01%
1.79%
5AM Venture Management, LLC
939,298US$13.2m0%2.99%
1.46%
OrbiMed Advisors LLC
768,638US$10.8m0%0.16%
1.39%
Frazier Life Sciences Management, LP
731,020US$10.3m-12.2%0.41%
0.99%
Geode Capital Management, LLC
523,190US$7.4m0.1%no data
0.97%
Perceptive Advisors LLC
511,226US$7.2m-49.3%0.17%
0.96%
Boxer Capital Management, LLC
504,729US$7.1m0%no data
0.89%
Kynam Capital Management, LP
467,947US$6.6m-17.4%0.55%
0.81%
Daniel Bensen
427,981US$6.0m0%no data
0.76%
Sio Capital Management, LLC
400,870US$5.6m-33.2%2.75%
0.73%
State Street Global Advisors, Inc.
384,732US$5.4m4.41%no data
0.64%
JP Morgan Asset Management
334,091US$4.7m1.24%no data
0.51%
Ally Bridge Group
270,075US$3.8m2.05%1.61%
0.41%
Northern Trust Global Investments
214,353US$3.0m37.9%no data
0.39%
Driehaus Capital Management LLC
203,709US$2.9m0%0.02%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/29 09:12
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Tyra Biosciences, Inc. is covered by 8 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Geoffrey MeachamBofA Global Research
Jason ZemanskyBofA Global Research
Mitchell KapoorH.C. Wainwright & Co.